Download video

Compugen Q2 2025 Earnings: Pipeline Potential vs. Revenue Miss

16 views

TalkTickers: AI Podcast Discussing Earnings Calls

Updated 3 days ago

Compugen Q2 2025 Earnings: Pipeline Potential vs. Revenue Miss

Compugen Q2 2025 Earnings: Pipeline Potential vs. Revenue Miss

P8 2
1:39
P8 2
by Ken zou
CapCO2 Solutions - September 2025 update
1:03
CapCO2 Solutions - September 2025 update
by CapCO2 Solutions
ch2 20250928074500 20250928083059
46:00
ch2 20250928074500 20250928083059
by IT Support
Bioinf Class 2C, Overview of 'secondary' databases
17:39
Bioinf Class 2C, Overview of 'secondary' databases
by NoorBioScience
PRC 5240320256
0:31
PRC 5240320256
by multimediaUEW 2025
C7u2p2
53:15
C7u2p2
by Jessica
Phase II study of petosemtamab and pembrolizumab for recurrent\/metastatic HNSCC
3:15
Phase II study of petosemtamab and pembrolizumab for recurrent\/metastatic HNSCC
by VJOncology
2025 top 25 point system
9:55
2025 top 25 point system
by Knumbskull News
km 20250624 1080p 50f 20250624 090143
13:36
km 20250624 1080p 50f 20250624 090143
by HR Economics Home
Lab Science: Ag progress Days (08\/12\/2025)
1:45
Lab Science: Ag progress Days (08\/12\/2025)
by PCNTV
Compugen CGEN Q2 2025 Earnings Call
25:53
Compugen CGEN Q2 2025 Earnings Call
by Fyfull
COn25OrgLogoVideo 2
2:00
COn25OrgLogoVideo 2
by GradLeaders
ch2 20251009200000 20251009203059
31:00
ch2 20251009200000 20251009203059
by IT Support
CKPG Today for October 2, 2025
22:57
CKPG Today for October 2, 2025
by CKPG Today Show
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
0:52
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
2025 10 SOC2
56:57
2025 10 SOC2
by RRCoP
10\/02\/2025 Cause Marketing Expo
2:13
10\/02\/2025 Cause Marketing Expo
by KPVM 25 TV